These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model. Akita M; Mizuno K; Matsubara A; Nakano K; Kurono M Acta Med Okayama; 1993 Oct; 47(5):299-304. PubMed ID: 8273453 [TBL] [Abstract][Full Text] [Related]
8. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Kador PF; Akagi Y; Takahashi Y; Ikebe H; Wyman M; Kinoshita JH Arch Ophthalmol; 1990 Sep; 108(9):1301-9. PubMed ID: 2119169 [TBL] [Abstract][Full Text] [Related]
9. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Dagher Z; Park YS; Asnaghi V; Hoehn T; Gerhardinger C; Lorenzi M Diabetes; 2004 Sep; 53(9):2404-11. PubMed ID: 15331552 [TBL] [Abstract][Full Text] [Related]
10. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. Neuenschwander H; Takahashi Y; Kador PF J Ocul Pharmacol Ther; 1997 Dec; 13(6):517-28. PubMed ID: 9436155 [TBL] [Abstract][Full Text] [Related]
11. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717 [TBL] [Abstract][Full Text] [Related]
12. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340 [TBL] [Abstract][Full Text] [Related]
13. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model. Robison WG; Laver NM; Jacot JL; Glover JP Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Obrosova IG; Maksimchyk Y; Pacher P; Agardh E; Smith ML; El-Remessy AB; Agardh CD Int J Mol Med; 2010 Jul; 26(1):135-42. PubMed ID: 20514433 [TBL] [Abstract][Full Text] [Related]
16. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Frank RN; Amin R; Kennedy A; Hohman TC Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227 [TBL] [Abstract][Full Text] [Related]
18. Extract of Polygonum cuspidatum Attenuates Diabetic Retinopathy by Inhibiting the High-Mobility Group Box-1 (HMGB1) Signaling Pathway in Streptozotocin-Induced Diabetic Rats. Sohn E; Kim J; Kim CS; Lee YM; Kim JS Nutrients; 2016 Mar; 8(3):140. PubMed ID: 26950148 [TBL] [Abstract][Full Text] [Related]
19. Effect of aldose reductase inhibitors on the progression of retinopathy in galactose-fed dogs. Akagi Y; Kador PF Exp Eye Res; 1990 Jun; 50(6):635-9. PubMed ID: 2115453 [TBL] [Abstract][Full Text] [Related]
20. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Kador PF; Akagi Y; Terubayashi H; Wyman M; Kinoshita JH Arch Ophthalmol; 1988 Aug; 106(8):1099-102. PubMed ID: 3401138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]